Liminal BioSciences announces FDA approval for its BLA of Ryplazim to treat patients with plasminogen deficiency type 1
Liminal BioSciences Inc. announced that the FDA has approved Ryplazim (plasminogen, human-tvmh) for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenia) through its subsidiary, Prometic Biotherapeutics… read more.
